What were the design, dosing regimen, and outcomes of the NRG‑GY018 phase III trial evaluating pembrolizumab (Keytruda) combined with carboplatin‑paclitaxel chemotherapy in patients with advanced (stage III–IVB) or recurrent endometrial carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NRG-GY018 Trial Design and Outcomes

The NRG-GY018 (KEYNOTE-868) trial demonstrated that pembrolizumab 200 mg every 3 weeks combined with carboplatin-paclitaxel chemotherapy for 6 cycles, followed by pembrolizumab 400 mg every 6 weeks maintenance for up to 14 additional cycles (total ~24 months), significantly improved progression-free survival in both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) advanced or recurrent endometrial cancer patients, establishing this as the new standard first-line treatment. 1, 2

Trial Design

This was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial that enrolled 810 patients with advanced or recurrent endometrial carcinoma 1, 2. The study stratified patients into two separate cohorts:

  • dMMR cohort: 222 patients (27%)
  • pMMR cohort: 588 patients (73%)

Eligibility Criteria

Patients were eligible if they had:

  • Measurable Stage III disease
  • Measurable Stage IVA disease
  • Stage IVB disease (with or without measurable disease)
  • Recurrent endometrial cancer (with or without measurable disease)

Critical inclusion: Patients must have received no prior systemic therapy OR had received prior adjuvant chemotherapy with a chemotherapy-free interval of at least 12 months 1.

Key exclusions: Endometrial sarcoma (including carcinosarcoma), active autoimmune disease, or conditions requiring immunosuppression 1.

Dosing Regimen

The treatment protocol consisted of two phases:

Induction Phase (6 cycles)

  • Pembrolizumab: 200 mg IV every 3 weeks
  • Paclitaxel: 175 mg/m² IV every 3 weeks
  • Carboplatin: AUC 5 mg/mL/min IV every 3 weeks

All medications administered on Day 1 of each 3-week cycle 1.

Important modification: Patients with measurable disease who achieved stable disease or partial response after cycle 6 could continue paclitaxel-carboplatin with pembrolizumab for up to 10 total chemotherapy cycles 1.

Maintenance Phase (up to 14 cycles)

  • Pembrolizumab: 400 mg IV every 6 weeks as monotherapy
  • Maximum total treatment duration: 20 cycles (~24 months) 1

Primary Outcomes: Progression-Free Survival

dMMR Cohort (Mismatch Repair-Deficient)

The results were dramatic: At 12 months, 74% of pembrolizumab-treated patients remained progression-free compared to only 38% with placebo-chemotherapy alone 2.

  • Hazard ratio: 0.30 (95% CI 0.19-0.48; P<0.001)
  • Risk reduction: 70% relative reduction in progression or death 2
  • This represents one of the most substantial treatment effects seen in gynecologic oncology

pMMR Cohort (Mismatch Repair-Proficient)

The benefit was more modest but still clinically meaningful:

  • Median PFS with pembrolizumab: 13.1 months
  • Median PFS with placebo: 8.7 months
  • Hazard ratio: 0.54 (95% CI 0.41-0.71; P<0.001) 2

Blinded Independent Central Review

Exploratory analysis using BICR confirmed the investigator-assessed findings 3:

  • pMMR cohort HR: 0.64 (95% CI 0.49-0.85; P=0.0008)
  • dMMR cohort HR: 0.45 (95% CI 0.27-0.73; P=0.0005)

Secondary Outcomes: Overall Survival

At the time of primary analysis, OS data were immature but showed favorable trends 3:

  • pMMR cohort HR: 0.79 (95% CI 0.53-1.17; 1-sided P=0.1157)
  • dMMR cohort HR: 0.55 (95% CI 0.25-1.19; 1-sided P=0.0617)

The OS benefit appears more pronounced in the dMMR population, though neither reached statistical significance at interim analysis 3.

Safety Profile

Adverse events were consistent with the known toxicity profiles of pembrolizumab and carboplatin-paclitaxel chemotherapy 2. The combination did not introduce unexpected safety signals, though immune-related adverse events must be monitored and managed appropriately.

Clinical Implementation

This trial directly led to FDA approval and guideline recommendations 4, 1:

  • For dMMR tumors: Pembrolizumab plus carboplatin-paclitaxel followed by pembrolizumab maintenance is now the preferred first-line therapy (Level I, Grade A evidence) 4
  • For pMMR tumors: This combination can be considered as first-line treatment (Level I, Grade B evidence) 4

Monitoring Schedule

Tumor assessment was performed:

  • Every 9 weeks for the first 9 months
  • Every 12 weeks thereafter 1

Key Clinical Pearls

The magnitude of benefit differs substantially by MMR status: The dMMR population derives exceptional benefit (70% risk reduction), while pMMR patients have more modest but still meaningful improvement. This underscores the critical importance of MMR testing before treatment initiation 4, 5.

Duration matters: The maintenance phase extends to approximately 24 months total, which is longer than some competing regimens and may impact cost-effectiveness 6.

Related Questions

What evidence supports the use of maintenance pembrolizumab (Keytruda) in metastatic endometrial cancer?
In a 52‑year‑old woman with advanced FIGO grade 1 endometrioid adenocarcinoma who received carboplatin, paclitaxel, and pembrolizumab and developed febrile neutropenia with persistent high fevers despite broad‑spectrum antibiotics, now has a recovered neutrophil count, what should hematology‑oncology’s next management be and what is the most likely cause of the ongoing high fevers?
What is the evidence for the combination of gemcitabine, carboplatin, and pembrolizumab in metastatic endometrial cancer?
What is the duration of maintenance pembrolizumab (pembrolizumab) therapy in patients with metastatic endometrial cancer?
Is there a trial of cetuximab combined with pembrolizumab and chemotherapy in patients with PD‑L1 combined positive score (CPS) ≥ 1?
What are the dosing recommendations for pantoprazole (Protonix) for gastro‑oesophageal reflux disease, gastric or duodenal ulcer, Helicobacter pylori infection, maintenance therapy, and renal impairment?
How should I adjust the levothyroxine dose for an adult patient taking 25 µg daily with a TSH of 6.93 mIU/L and a free T4 of 1.23 ng/dL?
Is guselkumab (Tremfya) safe for use in organ transplant patients?
What antipyretic medication is appropriate for a patient with liver failure who has a fever?
Can losartan (angiotensin II receptor blocker) cause xerostomia and decreased appetite?
What are the recommended PET‑CT scan timings for a Hodgkin lymphoma patient receiving Nivolumab (240 mg) plus AVD (doxorubicin, vinblastine, dacarbazine) chemotherapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.